This HTML5 document contains 130 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n23http://linked.opendata.cz/resource/AHFS/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01438/identifier/pubchem-substance/
n14http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01438/identifier/drugbank/
n25http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n22http://www.rxlist.com/cgi/generic/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01438/identifier/chemspider/
n26http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/medicinal-product/
n13http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n18http://www.drugs.com/cdi/
n5http://linked.opendata.cz/resource/drugbank/property/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01438/identifier/wikipedia/
n27http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01438/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/drugbank/drug/DB01438/identifier/kegg-compound/
n15http://linked.opendata.cz/ontology/sukl/drug/
n16http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01438/identifier/pubchem-compound/

Statements

Subject Item
n2:DB01438
rdf:type
n3:Drug
n3:description
A local anesthetic that has been used in urinary tract disorders. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity. [PubChem]
n3:group
approved
n3:halfLife
7.35 hours
n3:indication
For the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters.
owl:sameAs
n25:DB01438 n26:DB01438
dcterms:title
Phenazopyridine
adms:identifier
n7:46507962 n8:4756 n10:C07429 n11:4592 n12:DB01438 n19:PA164746899 n20:Phenazopyridine
n3:mechanismOfAction
Phenazopyridine's mechanism of action is not well known, and only basic information on its interaction with the body is available. It is known that the chemical has a direct topical analgesic effect on the mucosa lining of the urinary tract.
n3:packager
n4:271B4B0F-363D-11E5-9242-09173F13E4C5 n4:271B4B10-363D-11E5-9242-09173F13E4C5 n4:271B4B0D-363D-11E5-9242-09173F13E4C5 n4:271B4B0E-363D-11E5-9242-09173F13E4C5 n4:271B4B03-363D-11E5-9242-09173F13E4C5 n4:271B4B01-363D-11E5-9242-09173F13E4C5 n4:271B4B11-363D-11E5-9242-09173F13E4C5 n4:271B4B02-363D-11E5-9242-09173F13E4C5 n4:271B4AEB-363D-11E5-9242-09173F13E4C5 n4:271B4AEC-363D-11E5-9242-09173F13E4C5 n4:271B4B18-363D-11E5-9242-09173F13E4C5 n4:271B4B19-363D-11E5-9242-09173F13E4C5 n4:271B4B16-363D-11E5-9242-09173F13E4C5 n4:271B4AEF-363D-11E5-9242-09173F13E4C5 n4:271B4B17-363D-11E5-9242-09173F13E4C5 n4:271B4B07-363D-11E5-9242-09173F13E4C5 n4:271B4AF8-363D-11E5-9242-09173F13E4C5 n4:271B4B1C-363D-11E5-9242-09173F13E4C5 n4:271B4B08-363D-11E5-9242-09173F13E4C5 n4:271B4AED-363D-11E5-9242-09173F13E4C5 n4:271B4B1D-363D-11E5-9242-09173F13E4C5 n4:271B4AEE-363D-11E5-9242-09173F13E4C5 n4:271B4B1A-363D-11E5-9242-09173F13E4C5 n4:271B4AEA-363D-11E5-9242-09173F13E4C5 n4:271B4AFB-363D-11E5-9242-09173F13E4C5 n4:271B4B1B-363D-11E5-9242-09173F13E4C5 n4:271B4B0B-363D-11E5-9242-09173F13E4C5 n4:271B4AFC-363D-11E5-9242-09173F13E4C5 n4:271B4B20-363D-11E5-9242-09173F13E4C5 n4:271B4B0C-363D-11E5-9242-09173F13E4C5 n4:271B4AF9-363D-11E5-9242-09173F13E4C5 n4:271B4B09-363D-11E5-9242-09173F13E4C5 n4:271B4AFA-363D-11E5-9242-09173F13E4C5 n4:271B4B21-363D-11E5-9242-09173F13E4C5 n4:271B4B0A-363D-11E5-9242-09173F13E4C5 n4:271B4AFF-363D-11E5-9242-09173F13E4C5 n4:271B4B1E-363D-11E5-9242-09173F13E4C5 n4:271B4B1F-363D-11E5-9242-09173F13E4C5 n4:271B4B00-363D-11E5-9242-09173F13E4C5 n4:271B4AFD-363D-11E5-9242-09173F13E4C5 n4:271B4AFE-363D-11E5-9242-09173F13E4C5 n4:271B4B05-363D-11E5-9242-09173F13E4C5 n4:271B4B06-363D-11E5-9242-09173F13E4C5 n4:271B4B04-363D-11E5-9242-09173F13E4C5 n4:271B4B14-363D-11E5-9242-09173F13E4C5 n4:271B4B15-363D-11E5-9242-09173F13E4C5 n4:271B4B12-363D-11E5-9242-09173F13E4C5 n4:271B4B13-363D-11E5-9242-09173F13E4C5 n4:271B4AF7-363D-11E5-9242-09173F13E4C5 n4:271B4AF5-363D-11E5-9242-09173F13E4C5 n4:271B4AF6-363D-11E5-9242-09173F13E4C5 n4:271B4AF0-363D-11E5-9242-09173F13E4C5 n4:271B4AF3-363D-11E5-9242-09173F13E4C5 n4:271B4AF4-363D-11E5-9242-09173F13E4C5 n4:271B4AF1-363D-11E5-9242-09173F13E4C5 n4:271B4AF2-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
40% hepatic
n3:synonym
Fenazopiridina 3-(Phenylazo)-2,6-pyridinediamine
n3:toxicity
Methemoglobinemia generally follows a massive, acute overdose.
n15:hasAHFSCode
n23:84-08-00
n3:foodInteraction
Take with food to reduce irritation.
n3:salt
n13:hasConcept
n14:M0016493
foaf:page
n18:phenazopyridine.html n22:phenazopyridine.htm n27:pyr1365.shtml
n3:IUPAC-Name
n5:271B4B37-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B4B3D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B4B3C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B4B39-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B4B3A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B4B3B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B4B35-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B4B36-363D-11E5-9242-09173F13E4C5 n5:271B4B33-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B4B34-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n16:G04BX06
n3:H-Bond-Acceptor-Count
n5:271B4B43-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B4B44-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B4B3E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B4B3F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B4B41-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B4B40-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B4B42-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
94-78-0
n3:containedIn
n21:271B4B22-363D-11E5-9242-09173F13E4C5 n21:271B4B25-363D-11E5-9242-09173F13E4C5 n21:271B4B26-363D-11E5-9242-09173F13E4C5 n21:271B4B23-363D-11E5-9242-09173F13E4C5 n21:271B4B24-363D-11E5-9242-09173F13E4C5 n21:271B4B29-363D-11E5-9242-09173F13E4C5 n21:271B4B2A-363D-11E5-9242-09173F13E4C5 n21:271B4B27-363D-11E5-9242-09173F13E4C5 n21:271B4B28-363D-11E5-9242-09173F13E4C5 n21:271B4B2D-363D-11E5-9242-09173F13E4C5 n21:271B4B2E-363D-11E5-9242-09173F13E4C5 n21:271B4B2B-363D-11E5-9242-09173F13E4C5 n21:271B4B2C-363D-11E5-9242-09173F13E4C5 n21:271B4B2F-363D-11E5-9242-09173F13E4C5 n21:271B4B30-363D-11E5-9242-09173F13E4C5 n21:271B4B31-363D-11E5-9242-09173F13E4C5 n21:271B4B32-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B4B49-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B4B4B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B4B4C-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B4B4D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B4B48-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B4B47-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B4B4A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B4B38-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B4B45-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B4B46-363D-11E5-9242-09173F13E4C5